Larotrectinib Compared With Other TRK Inhibitors for TRK Fusion+ Lung Tumors

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the data supporting the use of larotrectinib (Vitrakvi) for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib (Rozlytrek).

Transcript:

0:08 | So, I think larotrectinib has the most robust data at this point, number of patients, etc than entrectinib. And it was different in the sense it's less of a nonspecific inhibitor. It also targets ROS, and those who are developing and entrectinib and involved with entrectinib will tell you that it may be an advantage. But it's interesting that the majority of patients who have NTRK fusions rarely have any other alterations, they just have NTRK fusions.

0:40 | So, my bias given the fact that I also helped develop this drug is that patients who have NTRK fusions should be getting an NTRK inhibitor of some sort. In my opinion, larotrectinib given the robustness of the data, the number of patients etc. Overall, the overall response rates are a little bit better with larotrectinib. Right now, it's not clear whether progression-free survival or overall survival are any better, but that's why I would consider larotrectinib.